Bionano Laboratories Announces Expansion of Diagnostic Testing Based on Optical Genome Mapping for Hematologic MalignanciesGlobeNewsWire · Sep 23, 2026
Bionano Announces Three New Peer-Reviewed Studies Demonstrate Clinical Value of Bionano's Optical Genome Mapping Across Myelodysplastic Syndromes and Acute Myeloid LeukemiaGlobeNewsWire · Sep 14, 2026
Bionano Laboratories Announces Proposed Local Coverage Determination (LCD) from MolDX for Genome-Wide Detection of Structural Variants in Hematologic NeoplasmsGlobeNewsWire · Sep 10, 2026
Bionano Laboratories Announces New York State Department of Health Approval of Lab Developed Tests Based on Optical Genome MappingGlobeNewsWire · Sep 8, 2026
Bionano to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewsWire · Aug 24, 2026
Bionano Genomics, Inc. (BNGO) Q2 2026 Earnings Call TranscriptSeeking Alpha · Aug 10, 2026Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 10, 2026 | -$0.67 | -$0.64 | Beat |
| May 13, 2026 | -$0.81 | -$0.76 | Beat |
| Mar 23, 2026 | -$0.81 | -$0.03 | Beat |
| Nov 13, 2025 | -$1.81 | -$1.59 | Beat |
| Aug 14, 2025 | -$2.69 | -$1.99 | Beat |
| May 14, 2025 | -$3.49 | -$1.15 | Beat |